Hematological Malignancies

Nurix Therapeutics Inc (NASDAQ: NRIX) announced initial data from Phase 1a trial of NX-2127 in relapsed or refractory B cell malignancies. Initial data from the first two completed cohorts of 100 mg and 200 mg, which included six patients, showed BTK levels in peripheral blood...

The FDA has accepted for review TG Therapeutics Inc's (NASDAQ: TGTX) marketing application seeking approval for ublituximab in combination with Ukoniq (umbralisib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The agency's action date is...

Trillium Therapeutics Inc (NASDAQ: TRIL) has provided a data update for TTI-622 and 621 programs in hematologic malignancies. As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses...

Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of next-generation ETBs. In November last year, FDA instituted a partial...